FibroGen Stock News

FibroGen, Inc. (FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with

FibroGen, Inc. (FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more th

Two Sigma Investments LP lowered its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 63.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Excha

Mackenzie Financial Corp bought a new stake in shares of FibroGen Inc (NASDAQ:FGEN) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 6,900 shares of the

Geode Capital Management LLC raised its holdings in FibroGen Inc (NASDAQ:FGEN) by 7.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,1

Novartis (NYSE: NVS) shares are trading higher on Wednesday after the company announced it received FDA approval for its Cosentyx for a new indication to treat active non-...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F

Details the CEO buys this past week for the following companies: FibroGen, Quidel, Camping World Holdings, B. Riley Financial and Ranpak Holdings Continue reading...

FibroGen (NASDAQ:FGEN) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, BidAs

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Kiniksa announces positive COVID-19 trial. Astellas Phase 3 anemia study reports positive data. Enochian BioSciences progresses with HIV drug.

Equities research analysts expect FibroGen Inc (NASDAQ:FGEN) to announce earnings per share (EPS) of ($0.59) for the current quarter, Zacks reports. Four analysts have provided estimates for FibroGen�